Dose-dense high-dose methylprednisolone and rituximab in the treatment of relapsed or refractory high-risk chronic lymphocytic leukemia

No abstract is available for this paper.

• Publication year

  2011

• Venue

  Leukemia and Lymphoma

• Publication date

  2011-05-23

• Fields of study

  Medicine

• Identifiers
  DOI 10.3109/10428194.2011.562572PMID 21599591
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Efficacy of lenalidomide in patients with chronic lymphocytic leukemia with high-risk cytogenetics

  2010cited by this paper
• Ofatumumab as single-agent CD20 immunotherapy in fludarabine-refractory chronic lymphocytic leukemia.

  2010cited by this paper
• Rituximab plus fludarabine and cyclophosphamide prolongs progression-free survival compared with fludarabine and cyclophosphamide alone in previously treated chronic lymphocytic leukemia.

  2010cited by this paper
• Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial.

  2010cited by this paper
• Rituximab in chronic lymphocytic leukemia.

  2010cited by this paper
• Subcutaneous alemtuzumab in fludarabine-refractory chronic lymphocytic leukemia: clinical results and prognostic marker analyses from the CLL2H study of the German Chronic Lymphocytic Leukemia Study Group.

  2009cited by this paper
• RITUXIMAB IN COMBINATION WITH HIGH DOSE METHYLPREDNISOLONE FOR THE TREATMENT OF CHRONIC LYMPHOCYTIC LEUKEMIA

  2009cited by this paper
• Clinical response and pharmacokinetics from a phase 1 study of an active dosing schedule of flavopiridol in relapsed chronic lymphocytic leukemia.

  2009cited by this paper
• Forodesine has high antitumor activity in chronic lymphocytic leukemia and activates p53-independent mitochondrial apoptosis by induction of p73 and BIM.

  2009cited by this paper
• High dose methylprednisolone and rituximab is an effective therapy in advanced refractory chronic lymphocytic leukemia resistant to fludarabine therapy

  2008cited by this paper
• Lenalidomide induces complete and partial remissions in patients with relapsed and refractory chronic lymphocytic leukemia.

  2008cited by this paper
• Bendamustine Is Effective in p53-Deficient B-Cell Neoplasms and Requires Oxidative Stress and Caspase-Independent Signaling

  2008cited by this paper
• High‐throughput amplicon scanning of the TP53 gene in breast cancer using high‐resolution fluorescent melting curve analyses and automatic mutation calling

  2008cited by this paper
• Rituximab in combination with high-dose methylprednisolone for the treatment of fludarabine refractory high-risk chronic lymphocytic leukemia

  2008influential reference
• Methylprednisolone-rituximab is an effective salvage therapy for patients with relapsed chronic lymphocytic leukemia including those with unfavorable cytogenetic features

  2007cited by this paper
• Alemtuzumab is an effective therapy for chronic lymphocytic leukemia with p53 mutations and deletions.

  2004cited by this paper
• Rituximab in chronic lymphocytic leukemia.

  2003cited by this paper
• Design and standardization of PCR primers and protocols for detection of clonal immunoglobulin and T-cell receptor gene recombinations in suspect lymphoproliferations: Report of the BIOMED-2 Concerted Action BMH4-CT98-3936

  2003cited by this paper
• High dose methylprednisolone can induce remissions in CLL patients with p53 abnormalities

  2003influential reference
• Interphase cytogenetic abnormalities in chronic lymphocytic leukemia may predict response to rituximab.

  2003cited by this paper
• Results of First Salvage Therapy for Patients Refractory to a Fludarabine Regimen in Chronic Lymphocytic Leukemia

  2002cited by this paper
• Rituximab using a thrice weekly dosing schedule in B-cell chronic lymphocytic leukemia and small lymphocytic lymphoma demonstrates clinical activity and acceptable toxicity.

  2001cited by this paper
• Rituximab dose-escalation trial in chronic lymphocytic leukemia.

  2001cited by this paper
• High dose methyl prednisolone in refractory chronic lymphocytic leukaemia.

  1999cited by this paper
• National Cancer Institute-sponsored Working Group guidelines for chronic lymphocytic leukemia: revised guidelines for diagnosis and treatment.

  1996cited by this paper
• p53 gene deletion predicts for poor survival and non-response to therapy with purine analogs in chronic B-cell leukemias.

  1995cited by this paper
• Survival of young patients with chronic lymphocytic leukemia failing fludarabine therapy: a basis for the use of myeloablative therapies.

  1995cited by this paper
• Methylprednisolone in advanced chronic lymphocytic leukaemia: rationale for, and effectiveness of treatment suggested by DiSC assay.

  1995cited by this paper

• Efficacy of high-dose corticosteroid-based treatment for chronic lymphocytic leukemia patients with p53 abnormalities in the era of B-cell receptor inhibitors.

  2020cites this paper
• T Regulatory Cells in Relapsed/Refractory Chronic Lymphocytic Leukemia Treated with High Dose Methylprednisolone and Rituximab

  2020influential citation
• Rituximab, Cyclophosphamide and Dexamethasone (RCD) Chemoimmunotherapy for Relapsed Chronic Lymphocytic Leukaemia

  2020cites this paper
• Dose Intensive Rituximab and High-Dose Methylprednisolone in Elderly or Unfit Patients with Relapsed Chronic Lymphocytic Leukemia

  2019cites this paper
• Molecular mechanisms contributing to glucocorticoid resistance in lymphoid malignancies

  2019cites this paper
• Chronic Lymphocytic Leukemia

  2019cites this paper
• Efficacy of Ibrutinib-Based Regimen in Chronic Lymphocytic Leukemia: A Systematic Review

  2019cites this paper
• Leukemia Current and Emerging Drug Therapies in Chronic Lymphocytic Leukemia

  2017cites this paper
• Léčba starších a komorbidních nemocných s chronickou lymfocytární leukemií

  2017cites this paper
• Treatment of chronic lymphocytic leukemia in older adults.

  2017cites this paper
• Dexamethasone-(C21-phosphoramide)-[anti-EGFR]: molecular design, synthetic organic chemistry reactions, and antineoplastic cytotoxic potency against pulmonary adenocarcinoma (A549)

  2016cites this paper
• Therapeutic Approach to Patients with Chronic Lymphocytic Leukemia and Significant Comorbid Conditions.

  2016cites this paper
• Dexamethasone-( c 21-phosphoramide )-[ anti-egFr ] : molecular design , synthetic organic chemistry reactions , and antineoplastic cytotoxic potency against pulmonary adenocarcinoma ( a 549 )

  2016cites this paper
• Ibrutinib for patients with relapsed or refractory chronic lymphocytic leukaemia with 17p deletion (RESONATE-17): a phase 2, open-label, multicentre study.

  2016cites this paper
• Refractory Chronic Lymphocytic Leukemia: A Therapeutic Challenge.

  2016cites this paper
• How I treat chronic lymphocytic leukemia in older patients.

  2015cites this paper
• Practical approach to management of chronic lymphocytic leukemia

  2015cites this paper
• Ofatumumab added to dexamethasone in patients with relapsed or refractory chronic lymphocytic leukemia: Results from a phase II study

  2015cites this paper
• Current concepts in diagnosis and treatment of chronic lymphocytic leukemia

  2015cites this paper
• Five years of experience with rituximab plus high-dose dexamethasone for relapsed/refractory chronic lymphocytic leukemia

  2015cites this paper
• aberací TP 53 Treatment of Chronic Lymphocytic Leukemia with TP 53 Aberrations

  2015cites this paper
• A new hope: novel therapeutic approaches to treatment of chronic lymphocytic leukaemia with defects in TP53

  2014cites this paper
• Primary refractory T‐cell prolymphocytic leukaemia treated with daily administration of Alemtuzumab plus high‐dose methylprednisolone

  2014cites this paper
• The combination of rituximab, bendamustine, and cytarabine for heavily pretreated relapsed/refractory cytogenetically high‐risk patients with chronic lymphocytic leukemia

  2013cites this paper
• Хронический лимфолейкоз высокого риска: история, определение, диагностика и лечениеХронический лимфолейкоз высокого риска: история, определение, диагностика и лечение

  2013cites this paper
• How I treat patients with relapsed chronic lymphocytic leukaemia

  2013cites this paper
• TP53 aberrations in chronic lymphocytic leukemia.

  2013cites this paper
• Chapter 5 TP 53 Aberrations in Chronic Lymphocytic Leukemia

  2013cites this paper
• FOR DIAGNOSIS AND TREATMENT OF CHRONIC LYMPHOCYTIC LEUKEMIA January 10 2013

  2013cites this paper
• Anti-CD20 monoclonal antibodies in chronic lymphocytic leukemia

  2013cites this paper
• For Peer Review Guidelines on the diag nosis, investigation and management of Chronic Lymphocytic Leukaemia

  2012cites this paper
• Molecular mechanisms of apoptosis induced by dexamethasone in chronic lymphocytic leukemia

  2012cites this paper
• Therapeutic advancement of chronic lymphocytic leukemia

  2012cites this paper
• Rituximab in combination with high-dose dexamethasone for the treatment of relapsed/refractory chronic lymphocytic leukemia.

  2012cites this paper
• Guidelines on the diagnosis, investigation and management of chronic lymphocytic leukaemia

  2012cites this paper
• The role of high-dose corticosteroids in the treatment of chronic lymphocytic leukemia

  2012cites this paper
• Leucémie lymphoïde chronique Chronic lymphocytic leukemia

  2012cites this paper